Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

BACKGROUND Historical accounts linking cancer and microbes date as early as four
millennia ago. After establishment of the germ theory of infectious diseases, clinical research …

The gut microbiota have long been recognized to play a key role in human health and
disease. Currently, several lines of evidence from preclinical to clinical research have …

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …

In contrast to normal type I collagen (Col1) heterotrimer (α1/α2/α1) produced by fibroblasts,
pancreatic cancer cells specifically produce unique Col1 homotrimer (α1/α1/α1). Col1 …

Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of
cancer therapy, most notably immunotherapy and its immune-related adverse effects. The …

The intestinal microbiota, composed of a large population of microorganisms, is often
considered a “forgotten organ” in human health and diseases. Increasing evidence indicates …

Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …